Masumori Naoya, Baba Tsuyoshi, Abe Teruo, Niwa Koji
Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Int J Urol. 2021 May;28(5):526-529. doi: 10.1111/iju.14499. Epub 2021 Jan 19.
To identify the most eagerly anticipated change resulting from hormone therapy using gender-affirming hormones for patients with gender incongruence undergoing a clinical trial.
Patients diagnosed with gender identity disorders based on the International Classification of Diseases 10th revision classification at three institutions in Japan for whom hormone therapy using gender-affirming hormones was initiated were analyzed. They were asked what the most anticipated change was due to gender-affirming hormone that they had thought of between giving informed consent and the first administration of the drug.
The responders were 336 transgender men who were administered androgens and 48 transgender women who received estrogens. The median age at commencement of hormone therapy was 24 years for transgender men and 28 years for transgender women. For transgender men, the most frequent answer was cessation of menses (52.7%) followed by a deepened voice (32.4%). For transgender women, breast development (35.4%) was the most anticipated change, followed by gynoid fat deposition (29.2%).
Cessation of menses in transgender men and breast development/gynoid fat deposition in transgender women might represent primary end-points in clinical trials evaluating the efficacy of hormonal treatment in these patients.
确定在一项针对性别不一致患者使用性别确认激素进行激素治疗的临床试验中，最令人期待的变化。
对日本三家机构中根据《国际疾病分类》第10版分类被诊断为性别认同障碍且开始使用性别确认激素进行激素治疗的患者进行分析。询问他们在签署知情同意书至首次用药期间，因性别确认激素而最期待的变化是什么。
应答者为336名接受雄激素治疗的跨性别男性和48名接受雌激素治疗的跨性别女性。跨性别男性开始激素治疗的中位年龄为24岁，跨性别女性为28岁。对于跨性别男性，最常见的答案是月经停止（52.7%），其次是声音变低沉（32.4%）。对于跨性别女性，乳房发育（35.4%）是最期待的变化，其次是臀部脂肪沉积（29.2%）。
跨性别男性的月经停止以及跨性别女性的乳房发育/臀部脂肪沉积可能代表评估这些患者激素治疗疗效的临床试验中的主要终点。
